Newsfile Corp
08 Mar 2026, 12:49 UTC · 28w ago
Verdict
Headline takes no side. We score VTGN −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Vistagen's PALISADE-3 clinical trial for fasedienol failed to meet its primary efficacy endpoint in the treatment of social anxiety disorder.
So whatThe failure of a Phase 3 study for a lead candidate typically eliminates the primary catalyst for company growth and drastically reduces the asset's valuation.
More negative than 99% of claims this week
Vistagen common stock fell over 81% to $0.88 per share following the announcement of the failed trial results on December 17, 2025.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 99% of claims this week
A federal securities class action lawsuit has been filed alleging Vistagen made false or misleading statements regarding the likelihood of the PALISADE-3 trial's success.
More negative than 90% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a federal securities class action lawsuit following a failed Phase 3 clinical trial and an 81% stock price drop.
More negative than 75% of ticker scores this week
Mentioned in the context of a securities class action lawsuit deadline.
More negative than 75% of ticker scores this week
Mentioned in the context of a securities class action lawsuit deadline.
More negative than 75% of ticker scores this week
Mentioned in the context of a securities class action lawsuit deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
40m ago
−56.1%
Price agrees with the score
$0.2670 vs $0.6077 close before publication (Mar 6) · not market-adjusted
VTGN chart →
